In a recent TATTON trial, the combination therapy of savolitinib and osimertinib showed encouraging anti-tumor activity in patients with MET-amplified/overexpressed EGFR-mutated advanced NSCLC who had previously experienced disease progression on EGFR TKIs [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.